QuickFee: Next one in Fintech Race 

Summary QuickFee shares have provided a positive return of 392.85% between 23 March-8 July, and the Company has achieved record lending in both the...

A Stock that Witnessed Best Operating Quarter in its History During...

The first six months of 2020 have been entirely shaped by COVID-19 pandemic and its aftermath. COVID-19 has wreaked havoc across the world derailing b...

Things to watch in banking and FUM space - CBA and MFG under Spotlig...

Summary Mortgage lending could drop with a probability of rise in defaults due to risks of high unemployment and end of fiscal support. Commonweal...

REFFIND’s WooBoard to Gain from Deployment as Essential Service in F...

Summary Technology has shaped new and innovative ways of doing business, and many organisations have a significant opportunity in the digitally dri...

Crowd Media’s Board and Management Instrumental in Achieving Co’s Mi...

Summary Crowd Media is a vertically integrated, millennial focussed, social media commerce business selling a growing number of products and servic...

Lens on three ASX-listed insurance companies: QBE, IAG and SUN

The insurance industry of Australia provides various life insurance, property and casualty, and health insurance coverage to both businesses and indiv...

Lendlease under the Radar: Watch out for these trends for Constructi...

Summary Though the real estate sector was adversely impacted during the COVID-19 crisis with experts believing that the housing market might slip b...

Investing Today: 3 Drivers that move the needle for consumer discret...

Summary Consumer discretionary sector is among the industries that are hardest hit by the COVID 19, leading to further changes in the business mode...

Materials sector Stocks reflecting movements on ASX ledger: ABC, ORA...

Summary As per its latest update, ABC expects no material impact on revenue up until June next year (the time when lime supply contract is due to e...

‘D’ for Disruptive or Defensive: Dexus and Downer Stocks under Spotl...

Summary Investors find defensive stocks attractive as they offer dividend payments and generally generate steady income, irrespective of the market...

Is there a scope for these Logistics Companies to see a Comeback- TC...

Summary Rising COVID-19 cases in Victoria and NSW appears that the states have entered the second phase of COVID-19. The NSW-Victoria border would...

SEEK on the Charter: A Glance at Recent Developments

SEEK Limited (ASX:SEK) is an operator of the online employment classified and education and training. The Company witnessed an impressive stock perfor...

Mesoblast was the top gainer on the ASX today; Let’s find out why

COVID-19 turmoil is a public health crunch, with staggering fatalities and human suffering beyond words. This unprecedented crisis is being deeme...

ASX-listed Dental Stocks: Is there any relief coming in? PSQ, ONT, S...

Due to the rising number of coronavirus infections, many businesses were shut down amid COVID-19-induced restrictions. At the same time, some business...

ASX-listed Digital Healthcare Stock Amid COVID-19: A Look At RAP, HR...

The healthcare sector across the world is struggling with the myriad challenges thrown by the COVID-19 pandemic, and virtual healthcare is fast becomi...

ASX biotech companies creating a pandemic-free buzz!

As on 19 June 2020, the “pneumonia-like” illness has taken 456,432 lives with 8,538,928 confirmed cases recorded worldwide.  And with...

Are Investors Buying these Healthcare Stocks: Starpharma, Sigma and...

The healthcare sector is a significant and complex sector comprising a variety of companies engaged in manufacturing, developing, and selling of medic...

Don’t Miss! Small-Cap Healthcare Players’ Continued Focus on Innovat...

In the healthcare world, the general trend has been that smaller biotech players work on the innovation angle with research and development activities...

3 Small-cap Healthcare Stocks to Watch Out For – IMM, IDX, AT1

Small-cap stocks are listed companies with market capitalisation varying from USD 300 million to USD 2 billion or less. And in these stocks, there are...

Noxopharm Presented Highly Encouraging Veyonda® Clinical Data at ASC...

Summary Noxopharm presented two sets of clinical data concerning the development of Veyonda® as a treatment for end-stage prostate cancer at AS...